Practical Approaches to Protein Formulation Development

  • Byeong S. Chang
  • Susan Hershenson
Part of the Pharmaceutical Biotechnology book series (PBIO, volume 13)


As is the case with other pharmaceuticals, formulation development is one of the critical steps in developing a protein as a therapeutic product. Development of stable protein formulations may require even more resources and effort than conventional small molecule pharmaceuticals. Proteins typically have more stability issues as a result of their complexity and delicate structural stability. Fortunately, a great deal of research regarding protein stability has been conducted and this information is readily available in the literature (reviewed by Manning et al., 1989; Chen, 1992; Ahern and Manning, 1992a; Ahern and Manning, 1992b; Arakawa et al., 1993; Cleland et al., 1993; Wang and Pearlman, 1993; Pearlman and Wang, 1996; Volkin and Middaugh, 1997). Ultimately, it would be ideal to be able to develop a pure pharmaceutical containing only the native protein. However, it is not practical to have only the native form of a protein in the formulation because the protein must be purified from a complex biological mixture containing a pool of other proteins which includes misfolded, denatured, and degraded forms of the same protein. Furthermore, a major challenge is to maintain the integrity of the purified protein during routine pharmaceutical processing, storage, handling, and delivery to the patient. One could envision achieving this goal by developing a formulation with perfect stability, i.e., no physical and chemical change in the protein. Becauise proteins are complex molecules composed of numerous reactive chemical groups and delicate three-dimensional structures, identifying a set of conditions to keep all components stable is virtually impossible. In general, commercial therapeutic protein formulations are developed under the assumption that some degree of physicochemical changes will occur during storage and handling.


Degradation Product Drug Substance Bovine Spongiform Encephalopathy Formulation Development Protein Formulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahern, T.J. and Manning, M.C., 1992a. Stability of protein pharmaceuticals, Part A: Chemical and physical pathways of protein degradation. Pharm. Biotech. Ser. Volume 2. Plenum Press, N.Y.Google Scholar
  2. Ahern, T.J. and Manning, M.C., 1992b. Stability of protein pharmaceuticals, Part B: In vivo pathways of degradation and strategies for protein stabilization. Pharm. Biotech. Ser. Volume 3. Plenum Press, N.Y.Google Scholar
  3. Arakawa, T., Prestrelski, S., Kinney, W., and Carpenter, J.F., 1993. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Delivery Rev. 10:1.CrossRefGoogle Scholar
  4. Brewster, M.E., Hora, M.S., Simpkins, J.W., and Bodor, N., 1991. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8:792.PubMedCrossRefGoogle Scholar
  5. Cleland, J.L., Powell, M.F., and Shire, S.J., 1993. The development of stable protein formulations—A close look at protein aggregation, deamidation and oxidation. Crit. Rev. Ther. Drug 11:60.Google Scholar
  6. Chen, T., 1992. Formulation concerns of protein drugs. Drug Dev. Ind. Pharmacy, 18:1311.CrossRefGoogle Scholar
  7. Defelippis, M.R., Bakaysa, D.L., Bell, M.A., Heady, M.A., Li, S., Pye, S., Youngman, K.M., Radzuik, J., and Frank, B.H., 1998. Preparation and characterization of a cocrystalline suspension of [Lys(B28),Pro(B29)] human insulin analogue. J. Pharm. Sci. 87:170.PubMedCrossRefGoogle Scholar
  8. Fagain, C.O., 1995. Understanding and increasing protein stability. Biochimica et Biophysica Acta. 1252:1.PubMedCrossRefGoogle Scholar
  9. Francis, G.E., Fisher, D., Delgado, C., Malik, F., Gardiner, A., and Neale, D., 1998. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques Int. J. Hematology. 68:1.CrossRefGoogle Scholar
  10. Fransson, J., Hallen, D., and Florin-Robertsson, E., 1997. Solvent effects on the solubility and physical stability of human Insulin-like Growth Factor I. Pharm. Res. 14:606.PubMedCrossRefGoogle Scholar
  11. Grimm, W., 1998. Extension of the international conference on harmonization tripatic guieline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev. Indust. Pharm. 24:313.CrossRefGoogle Scholar
  12. Guerra, P.I., Acklin, C., Kosky, A.A., Davis, J.M., Treuheit, M.J., and Brems, D.N., 1998. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor Pharm. Res. 15:1822.PubMedCrossRefGoogle Scholar
  13. Herron, J.N., Jiskoot, W., and Crommelin, D.J.A., 1995. Physical methods to characterize pharmaceutical proteins. Pharm. Biotech. Ser. Volume 7. Plenum Press, N.Y.Google Scholar
  14. Jones, A.J.S., 1993. Analysis of polypeptides and proteins Adv. Drug Del Rev. 10:29.CrossRefGoogle Scholar
  15. Knepp, V.M., Muchnik, A., Oldmark, S., and Kalashnikova, L., 1998. Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm. Res. 15:1090.PubMedCrossRefGoogle Scholar
  16. Kolvenbach, C.G., Narhi, L.O., Philo, J.S., Li, T., Zhang, M., and Arakawa, T., 1997. Gran-ulocyte-colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2 J. Pept. Res. 50:310.PubMedCrossRefGoogle Scholar
  17. Kommanaboyina, B. and Rhodes, C.T., 1999. Trends in stability testing with emphasis on stability during distribution and storage. Drug Dev. Indust. Pharm. 25:857.CrossRefGoogle Scholar
  18. Lam, X.M., Patapoff, T.W., and Nguyen, T.H., 1997. The effect of benzyl alcohol on recombinant human interferon-gamma Pharm. Res. 14:725.PubMedCrossRefGoogle Scholar
  19. Maa, Y.F. and Hsu, C.C., 1996. Aggregation of recombinant human growth hormone induced by phenolic compounds Int. J. Pharm. 140:155.CrossRefGoogle Scholar
  20. Manning, M.C., Matsuura, J.E., Kendrick, B.S., Meyer, J.D., Dormish, J.J., Vrkljan, M., Ruth, J.R., Carpenter, J.F., and Shefter, E., 1995. Approaches for increasing the solution stability of proteins Biotech. Bioeng. 48:506.CrossRefGoogle Scholar
  21. Manning, M.C., Patel, K., and Borchardt, R.T., 1989. Stability of protein pharmaceuticals. Pharm. Res. 6:903.PubMedCrossRefGoogle Scholar
  22. Matthews, B.R., 1999. Regulatory aspects of stability testing in Europe. Drug Dev. Indust. Pharm. 25:831.CrossRefGoogle Scholar
  23. Murby, M., Samuelsson, E., Nguyen, T.N., Mignard, L., Power, U., Binz, H., Uhlen, M., and Stahl, S., 1995. Hydrophobility engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 230:38.PubMedCrossRefGoogle Scholar
  24. Nema, S., Washkuhn, R.J., and Brendel, RJ., 1997. Excipients and their use in injectable products PDA J. Pharm. Sci. Technol. 51:166.PubMedGoogle Scholar
  25. Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products, 1997. (CPMP/CVMP/QWP/115/95) EMEA (7/97).Google Scholar
  26. Pearlman, R. and Wang, Y.J., 1996. Formulation, characterization, and stability of protein drugs: case histories. Pharm. Biotech. Ser. Volume 9. Plenum Press, N.Y.Google Scholar
  27. Powell, M.F., Nguyen, T., and Baloian, L., 1998. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 52:238.PubMedGoogle Scholar
  28. Reubsaet, J.L.E., Beijnen, J.H., Bult, A., Van-Maanen, R.J., Marchai, J.A.D., and Under-berg, W.J.M., 1998. Analytical techniques used to study the degradation of proteins and peptides: chemical instability J. Pharm. Biomed. Anal. 17:955.PubMedCrossRefGoogle Scholar
  29. Roig, M.G. and Kennedy, J.F., 1995. Perspectives for biophysicochemical modifications of enzymes. J. Biomaterials Sci. Polymer Ed. 7:1.CrossRefGoogle Scholar
  30. Thompson, J.E., 1998. Practical Guide to Contemporary Pharmacy Practice. Lippincott Williams & Wilkins, Hagerstown, MD.Google Scholar
  31. Volkin, D.B., Mach, H., and Middaugh, CR., 1997. Degradative covalent reactions important to protein Stability. Molec. Biotech. 8:5.Google Scholar
  32. Wang, Y.J. and Hanson, M.A., 1988. Parenteral formulations of proteins and peptides: stability and stabilizers. J. Parent. Sci. Technol. 42:SS4.Google Scholar
  33. Wang, Y.J. and Pearlman, R., 1993. Stability and characterization of protein and peptide drugs: case histories. Pharm. Biotech. Ser. Volume 5. Plenum Press, N.Y.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Byeong S. Chang
    • 1
  • Susan Hershenson
    • 1
  1. 1.Department of Pharmaceutics and Drug DeliveryAmgen, Inc.Thousand OaksUSA

Personalised recommendations